5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders

5-HT2Receptor Distribution Shown by [18F] Setoperone PET in High-Functioning Autistic Adults

(2013) David Q. Beversdorf et al.   JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease

(2012) Diana L. Price et al.   BEHAVIOURAL PHARMACOLOGY

Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes

(2012) Jelle Vehof et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Off-label uses of trazodone: a review

(2012) Letizia Bossini et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day

(2012) Herbert Y. Meltzer et al.   SCHIZOPHRENIA RESEARCH

Serotonin 2A receptor antagonists for treatment of schizophrenia

(2011) Bjørn H Ebdrup et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

(2011) Klaus Seppi et al.   MOVEMENT DISORDERS

Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: Quantitative analysis, test–retest reproducibility, and vulnerability to endogenous 5-HT tone

(2011) Peter S. Talbot et al.   NEUROIMAGE

2.277 OPTIMIZATION OF PHASE III STUDY DESIGN FOR PIMAVANSERIN IN THE TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS (PDP)

(2011) R. Mills et al.   PARKINSONISM & RELATED DISORDERS

Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder

(2011) F W Lohoff et al.   PHARMACOGENOMICS JOURNAL

The 5-HT 2A receptor and serotonin transporter in Asperger's Disorder: A PET study with [ 11 C]MDL 100907 and [ 11 C]DASB

(2011) Ragy R. Girgis et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers

(2011) Sonia Ancoli-Israel et al.   SLEEP MEDICINE

Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia

(2010) Hans Rasmussen et al.   ARCHIVES OF GENERAL PSYCHIATRY

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

(2010) Benedicte Ballanger et al.   ARCHIVES OF NEUROLOGY

Increased 5-HT2Areceptors in the temporal cortex of parkinsonian patients with visual hallucinations

(2010) Philippe Huot et al.   MOVEMENT DISORDERS

Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study

(2010) Lisbeth Marner et al.   NEUROBIOLOGY OF AGING

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine

(2010) Hans Rasmussen et al.   PSYCHOPHARMACOLOGY

Serotonergic System Genes in Psychosis of Alzheimer Dementia: Meta-Analysis

(2009) Seethalakshmi Ramanathan et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Candidate gene studies of ADHD: a meta-analytic review

(2009) Ian R. Gizer et al.   HUMAN GENETICS

Brain serotonin 2A receptor binding: Relations to body mass index, tobacco and alcohol use

(2009) D. Erritzoe et al.   NEUROIMAGE

Familial Risk for Mood Disorder and the Personality Risk Factor, Neuroticism, Interact in Their Association with Frontolimbic Serotonin 2A Receptor Binding

(2009) Vibe G Frokjaer et al.   NEUROPSYCHOPHARMACOLOGY

Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET

(2009) Lekshmi Santhosh et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

Genetic variation in the serotonin 2A receptor and suicidal ideation in a sample of 270 Irish high-density schizophrenia families

(2008) Ayman H. Fanous et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2Areceptor gene in patients with schizophrenia responsive to antipsychotics

(2008) Dalila Benmessaoud et al.   BMC Psychiatry

Serotonin Receptors

(2008) David E. Nichols et al.   CHEMICAL REVIEWS

5-HT2A Inverse-Agonists for the Treatment of Insomnia

(2008) Bradley Teegarden et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder

(2008) Daniela Perani et al.   NEUROIMAGE

Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

(2008) M J V Wilkie et al.   PHARMACOGENOMICS JOURNAL

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model

(2008) K VANOVER et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Association study between obsessive–compulsive disorder and serotonergic candidate genes

(2008) Pilar A. Saiz et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

(2008) Borwin Bandelow et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Frontolimbic Serotonin 2A Receptor Binding in Healthy Subjects Is Associated with Personality Risk Factors for Affective Disorder

(2007) Vibe G. Frokjaer et al.   BIOLOGICAL PSYCHIATRY

Reduced 5-HT2A receptor binding in patients with mild cognitive impairment

(2007) S.G. Hasselbalch et al.   NEUROBIOLOGY OF AGING